In a model of RA in which autoantibodies from arthritogenic K/BxN drive inflammation and tissue destruction in serum-recipient mice, treatment with anti-JAM-A mAb delayed the disease onset and partially ameliorated overall disease (61). The gene discussed is F11R; the disease is rheumatoid arthritis.